Active material: Framycetin
When ATH: R01AX08
CCF: Antibacterial drug for local use in ENT practice
ICD-10 codes (testimony): J00, J01, J31, J32, Z29.2, Z29.8
When CSF: 06.05.04
Manufacturer: Laboratoires Bouchara-RECORDATI (France)
DOSAGE FORM, COMPOSITION AND PACKAGING
|Spray nazalynыy 1.25%||1 ml|
|framycetin sulfate||12.5 mg (8 th. ME)|
Excipients: metilparagidroksiʙenzoat, sodium chloride, lemon acid, water distillirovannaya.
15 ml – plastic bottles (1) Included spray – packs cardboard.
Aminoglycoside antibiotic for topical use in otorhinolaryngology. Effective bactericidal. It is active against Gram-positive and Gram-negative bacteria, causing the development of infectious processes in the upper respiratory tract.
Research pharmacokinetics Izofra not conducted in connection with low systemic absorption.
In the combined therapy in infectious and inflammatory diseases of the upper respiratory tract, including:
- Sinusitis (in the absence of damage to walls);
Prevention and treatment of inflammatory processes after surgery.
Adults appoint 1 injection into each nostril 4-6 time / day.
Babies appoint 1 injection into each nostril 3 times / day.
The average duration of therapy – 7 days.
By drinking a bottle should be kept in the upright position.
Allergic reactions: in a few cases – cutaneous manifestations.
- Hypersensitivity to framycetin and other antibiotics of the aminoglycoside.
Pregnancy and lactation
Adequate and well-controlled clinical studies safety of the drug Izofra during pregnancy and lactation (breast-feeding) not performed.
If during the 7 days of treatment with a therapeutic effect is weak or absent, the drug should be abolished.
Due to the low degree of absorption into the systemic circulation overdose is unlikely.
No clinically significant drug interactions Izofra with other drugs have been identified.
Conditions of supply of pharmacies
The drug is released under the prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored at temperatures above 25 ° C. Shelf life – 3 year.